This dual strategy addresses a critical barrier in treating cold tumors like OS and could potentially be extrapolated to other malignancies where high serum CXCL10 correlates with poor prognosis, such as melanoma and hepatocellular carcinoma [188,194,195,196,197]. Here, CXCL10 is linked to hepatocellular carcinoma.